Blood
Articles in this Issue
Chaudhury S, Reshef R, Nikiforow S, et al. Subgroup analysis in pediatric patients from the phase 3 study of tabelecleucel for allogeneic or solid organ transplant recipients with Epstein–Barr virus-driven post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE). <i>Blood.</i> 2025;146(suppl 1):5488.
An X. Rbm38 binds <i>Fech</i> pre-mRNA to prevent anemia and porphyria. <i>Blood</i> . 2025;146(25):3016-3017.
Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy
Abstract Quadruplet (QUAD) induction and autologous stem cell transplantation (ASCT) leads to high rates of measurable residual disease (MRD) negativity with improved outcomes in m...
Cloudy with a chance of platelets: forecasting chronic ITP
Mapping risk and therapy in secondary CNS lymphoma
A compartmentalized inflammatory landscape and macrophage plasticity regulate <i>Tet2</i> <i>+/−</i> -mediated clonal hematopoiesis
Abstract Clonal hematopoiesis of indeterminate potential (CHIP) is driven by hematopoietic stem cells carrying leukemia-associated mutations that expand in the bone marrow. Several...
Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma
Abstract Secondary central nervous system (CNS) large B-cell lymphoma (SCNSL) occurs in the de novo setting, as a CNS-isolated relapse, or synchronous (concomitant CNS and systemic...
Hot niches, cold niches, and the clone within
<i>GRK5</i> polymorphism turns up the volume on PAR1
Predicting development of pediatric chronic immune thrombocytopenia at disease onset using a statistical risk model
Abstract Immune thrombocytopenia (ITP) is associated with a variable and unpredictable clinical course in children, including a spectrum of bleeding and systemic symptoms in the mo...
Does minimal residual disease matter in t(11;14) myeloma?
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies
Abstract Patients with T-cell lymphomas and leukemias have overall poor outcomes because of the lack of targeted and effective treatments, particularly in the relapsed and refracto...
Transient aberrant plasma cells in a young patient with chronic inflammatory disease
Nikiforow S, Mahadeo K, Chaganti S, et al. Subgroup analysis based on prior treatment from the phase 3 allele study of tabelecleucel for epstein-barr virus-driven post-transplant lymphoproliferative disease [abstract]. <i>Blood.</i> 2025;146(suppl 1):1934.
Understanding how a highly prevalent <i>GRK5</i> polymorphism affects platelets and enhances thrombotic risk
Abstract Inherited genetic variants that modulate platelet function contribute significantly to thrombotic disorders, yet their mechanisms and clinical implications remain underexp...
How I treat breakthrough thrombosis in patients with cancer
Abstract Patients with cancer face an increased risk of venous thromboembolism (VTE), and breakthrough thrombosis despite anticoagulation, with a 6-month cumulative incidence of 5%...
Reviving CD2 signaling to boost CAR T-cell therapy
Chronic ITP prediction model
The singularity of IGHV4-34 links infection, autoimmunity, and B-cell tumors
Abstract B cells expressing the IGHV4-34 gene sit at the center of a web of B-cell functions, ranging from natural antibodies induced by infection to autoimmunity and tumors. Track...